Navigation Links
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Date:7/30/2014

ents.

Regeneron Forward-Looking Statements
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation alirocumab; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials, such as the ODYSSEY global trial program evaluating alirocumab; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, such as alirocumab, including the impact (if any) of the planned use of the U.S. Food and Drug Administration's Rare Pediatric Disease Priority Review Voucher in connection with the contemplated Biologics License Application submission for alirocumab; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates; the ability
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
2. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
3. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
4. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
5. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
8. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
9. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
10. Regeneron Announces March 2012 Investor Conference Presentations
11. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Edwardsville, Ill. (PRWEB) October 31, 2014 ... Edwardsville’s Department of Historical Studies within the College of ... at SIUE to record the history of alcohol-based fuels ... politicians, and many others have been working to build ... an important but overlooked aspect of the state's agricultural ...
(Date:10/31/2014)... The report "Dairy Alternative (Beverage) Market ... Sweetened, Unsweetened), Channel (Supermarket, Health Store, Pharmacy, Convenience ... to 2018," defines and segments the dairy alternative ... revenue and volume for plant-based dairy alternative beverages. ... $14 Billion by 2018 with the Asia-Pacific region ...
(Date:10/31/2014)... New York, NY (PRWEB) October 31, 2014 ... sectors such as healthcare, construction, finance and consumer ... applications. For this reason, industry research firm IBISWorld ... Software industry to its growing industry report collection. ... that develop software for biometric technologies such as ...
(Date:10/30/2014)... The report “Fragrance Ingredients Market by Type (Essential ... and Soaps & Detergents) & by Geography - Global ... the Fragrance Ingredients Market with analyses and projection of ... market has been segmented on the basis of major ... and Rest of the World (ROW); and their value ...
Breaking Biology Technology:SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 4Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 5
... Expedites Reporting Process, WALL, N.J., Oct. 24 ... leader in wireless public safety,solutions and finger based ... from the Littleton, Colorado Police Department,to implement the ... is a module of BIO-key,s Mobile Office(TM) solution. ...
... SAN FRANCISCO, Oct. 24 Cell Therapeutics,Inc. ... data presented at,the 19th annual AACR-NCI-EORTC Symposium ... kill tumors refractory to currently,marketed platinum agents ... human clinical trials in late 2008. ...
... (Nasdaq: KERX ) will hold a conference call ... discuss the Third Quarter 2007 financial results.,Michael S. Weiss, ... the call. Keryx will announce its financial results for ... to the call. In order to participate in ...
Cached Biology Technology:BIO-key(R) Awarded Contract to Deploy Incident Reporting System for Littleton, CO Police Department 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 3Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT 2
(Date:10/30/2014)... German . ... to behave socially? This is one of the central ... studies assumed that it is almost impossible to control ... Planck Institute for Evolutionary Biology have now demonstrated that ... cooperative behaviour of others. However, the possibilities available to ...
(Date:10/30/2014)... 29, 2014  Securus Technologies, a leading ... solutions for public safety, investigation, corrections and ... exciting enhancements to its THREADS™ product, which ... actionable intelligence and focused leads for investigators. ... technological innovation through identifying and delivering solutions ...
(Date:10/29/2014)... open for the Society of Interventional Radiology,s ... is the one place where interventional radiologists, ... care professionals can come together to find ... being presented, discussed and tested. , ... image-guided medicine, SIR 2015 will feature essential ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... Tenn. Consider the case of the three-spine stickleback. ... fresh water might appear to be the same, yet ... collection of very specialized individuals. Understanding the ... the goal of a group of scientists meeting at ...
... Stephania Cormier, PhD, Associate Professor of Pharmacology ... shown for the first time that early exposure ... ultrafine particulate matter) affects long-term lung function. She ... 11th International Congress on Combustion By-Products and Their ...
... research that allows farmers to harvest rice earlier, giving them ... needed food and ease hunger during monga -- the hunger ... northwest Bangladesh from September to November after the previous season,s ... rice in December. According to the Bangladesh Bureau ...
Cached Biology News:The value of variation: Ecologists consider the causes and consequences 2LSUHSC shows for first time infant inhalation of ultrafine air pollution linked to adult lung disease 2Early rice harvests ease annual famine in Bangladesh 2
... to detect the appearance of AcNPV gp64 ... as early as 8-24 hours post-infection. This ... Kit, which allows determination of baculovirus titers ... FastPlax Antibody can also be used to ...
synaptotagmin XIV-like [Source:RefSeq_peptide;Acc:NP_114120] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Goat polyclonal to SIAH Interacting Protein ( Abpromise for all tested applications)....
MAb to Transferrin Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Biology Products: